Surface plasmon resonance imaging detection of silver nanoparticle-tagged immunoglobulin

This article is available open access through the publisher’s website at the link below. Copyright @ 2011 The Royal Society.The detection sensitivity of silver nanoparticle (AgNP)-tagged goat immunoglobulin G (gIgG) microarrays was investigated by studying surface plasmon resonance (SPR) images captured in the visible wavelength range with the help of a Kretchmann-configured optical coupling set-up. The functionalization of anti-gIgG molecules on the AgNP surface was studied using transmission electron microscopy, photon correlation measurements and UV–visible absorption spectroscopy. A value of 1.3 × 107 M−1 was obtained for the antibody–antigen binding constant by monitoring the binding events at a particular resonance wavelength. The detection limit of this SPR imaging instrument is 6.66 nM of gIgG achieved through signal enhancement by a factor of larger than 4 owing to nanoparticle tagging with the antibody.The European Commissio

Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study

BackgroundAllergic rhinoconjunctivitis is an increasingly common source of morbidity, with sensitivity to cats accounting for 10% to 15% of disease burden. Allergy to cats is also a major risk factor for the development of asthma.ObjectivesWe sought to probe the persistence of the treatment effect of a novel Fel d 1–derived peptide antigen desensitization (Cat-PAD) 1 year after the start of treatment in subjects with cat allergy–induced rhinoconjunctivitis after standardized allergen challenge.MethodsIn a randomized, double-blind, placebo-controlled, parallel-group clinical trial, subjects attended an environmental exposure chamber in which they were exposed to cat allergen before and after treatment with 2 different regimens of Cat-PAD over a 3-month period. Clinical efficacy was assessed as a change in total rhinoconjunctivitis symptom scores 18 to 22 weeks and 50 to 54 weeks after the start of treatment.ResultsTreatment with Cat-PAD showed greater efficacy with 4 administrations of a 6-nmol dose 4 weeks apart than with 8 administrations of a 3-nmol dose 2 weeks apart. The treatment effect of 6 nmol persisted 1 year after the start of treatment and was significantly different from that of 3 nmol (P = .0342) and placebo (P = .0104). The treatment effect was apparent on both nasal and ocular symptoms at 1 year.ConclusionsA short course of Cat-PAD improves the ocular and nasal components of rhinoconjunctivitis symptoms in subjects with cat allergy, with the treatment effect persisting 1 year after the start of treatment

Polyurethane Membranes Modified with Isopropyl Myristate as a Potential Candidate for Encapsulating Electronic Implants: A Study of Biocompatibility and Water Permeability

Medical polyurethanes have shown good bio-stability and mechanical properties and have been used as coating for implantable medical devices. However, despite their excellent properties, they are relatively permeable to liquid water and water vapour which is a drawback for electronic implant encapsulation. In this study polyether polyurethanes with different soft segment molecular weights were modified by incorporating isopropyl myristate (IPM), as a hydrophobic modifying agent, and the effect of IPM on water resistant and biocompatibility of membranes were investigated. IPM changed the surface properties of the polyurethane film and reduced its surface energy. Polyurethane films were found to be stable with IPM concentrations of 1–5 wt% based upon their chemistry; however it leached out in BSA at higher concentrations. Though, low concentrations of IPM reduced both liquid water and water vapour permeability; at higher IPM content liquid permeability did not improved significantly. In general, the polyurethane materials showed much lower water permeability compared with currently used silicone packaging material for electronic implants. In addition, cytotoxicity assessment of IPM containing polyurethanes showed no evidence of cytotoxcity up to 5 wt% IPM

Isopropyl Myristate-Modified Polyether-Urethane Coatings as Protective Barriers for Implantable Medical Devices

Polyurethane films have potential applications in medicine, especially for packaging implantable medical devices. Although polyether-urethanes have superior mechanical properties and are biocompatible, achieving water resistance is still a challenge. Polyether based polyurethanes with two different molecular weights (PTMO1000, PTMO2000) were prepared from 4,4’-diphenylmethane diisocyanate and poly(tetra-methylene oxide). Polymer films were introduced using different concentrations (0.5-10 wt %) of isopropyl myristate lipid (IPM) as a non-toxic modifying agent. The physical and mechanical properties of these polymers were characterised using physical and spectroscopy techniques (FTIR, Raman, DSC, DMA, tensile testing). Water contact angle and water uptake of the membranes as a function of IPM concentration was also determined accordingly. The FTIR and Raman data indicate that IPM is dispersed in polyurethane at ≤ 2wt% and thermal analysis confirmed this miscibility to be dependent on soft segment length. Modified polymers showed increased tensile strength and failure strain as well as reduced water uptake by up to 24% at 1-2 wt% IPM